178 related articles for article (PubMed ID: 37766168)
1. Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy.
Chiuppesi F; Ortega-Francisco S; Gutierrez MA; Li J; Ly M; Faircloth K; Mack-Onyeike J; La Rosa C; Thomas S; Zhou Q; Drake J; Slape C; Fernando P; Rida W; Kaltcheva T; Grifoni A; Sette A; Patterson A; Dempsey S; Ball B; Ali H; Salhotra A; Stein A; Nathwani N; Rosenzweig M; Nikolaenko L; Al Malki MM; Dickter J; Nanayakkara DD; Puing A; Forman SJ; Taplitz RA; Zaia JA; Nakamura R; Wussow F; Diamond DJ; Dadwal SS
Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766168
[TBL] [Abstract][Full Text] [Related]
2. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants.
Chiuppesi F; Zaia JA; Faircloth K; Johnson D; Ly M; Karpinski V; La Rosa C; Drake J; Marcia J; Acosta AM; Dempsey S; Taplitz RA; Zhou Q; Park Y; Ortega Francisco S; Kaltcheva T; Frankel PH; Rosen S; Wussow F; Dadwal S; Diamond DJ
iScience; 2022 Aug; 25(8):104745. PubMed ID: 35846380
[TBL] [Abstract][Full Text] [Related]
3. Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus.
Chiuppesi F; Zaia JA; Gutierrez-Franco MA; Ortega-Francisco S; Ly M; Kha M; Kim T; Dempsey S; Kar S; Grifoni A; Sette A; Wussow F; Diamond DJ
Commun Med (Lond); 2024 Feb; 4(1):19. PubMed ID: 38366141
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial.
Chiuppesi F; Zaia JA; Frankel PH; Stan R; Drake J; Williams B; Acosta AM; Francis K; Taplitz RA; Dickter JK; Dadwal S; Puing AG; Nanayakkara DD; Ash P; Cui Y; Contreras H; La Rosa C; Tiemann K; Park Y; Medina J; Iniguez A; Zhou Q; Karpinski V; Johnson D; Faircloth K; Kaltcheva T; Nguyen J; Kha M; Nguyen VH; Francisco SO; Grifoni A; Wong A; Sette A; Wussow F; Diamond DJ
Lancet Microbe; 2022 Apr; 3(4):e252-e264. PubMed ID: 35287430
[TBL] [Abstract][Full Text] [Related]
5. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates.
Chiuppesi F; Nguyen VH; Park Y; Contreras H; Karpinski V; Faircloth K; Nguyen J; Kha M; Johnson D; Martinez J; Iniguez A; Zhou Q; Kaltcheva T; Frankel P; Kar S; Sharma A; Andersen H; Lewis MG; Shostak Y; Wussow F; Diamond DJ
NPJ Vaccines; 2022 Jan; 7(1):7. PubMed ID: 35064109
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates.
Chiuppesi F; Nguyen VH; Park Y; Contreras H; Karpinski V; Faircloth K; Nguyen J; Kha M; Johnson D; Martinez J; Iniguez A; Zhou Q; Kaltcheva T; Frankel P; Kar S; Sharma A; Andersen H; Lewis MG; Shostak Y; Wussow F; Diamond DJ
bioRxiv; 2021 Sep; ():. PubMed ID: 34545366
[TBL] [Abstract][Full Text] [Related]
7. Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants.
Wussow F; Kha M; Kim T; Ly M; Yll-Pico M; Kar S; Lewis MG; Chiuppesi F; Diamond DJ
NPJ Vaccines; 2023 Mar; 8(1):41. PubMed ID: 36928589
[TBL] [Abstract][Full Text] [Related]
8. COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants.
Wussow F; Kha M; Faircloth K; Nguyen VH; Iniguez A; Martinez J; Park Y; Nguyen J; Kar S; Andersen H; Lewis MG; Chiuppesi F; Diamond DJ
iScience; 2022 Jun; 25(6):104457. PubMed ID: 35634578
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
medRxiv; 2024 Jan; ():. PubMed ID: 38343800
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
[TBL] [Abstract][Full Text] [Related]
11. Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations.
Titova E; Kan VW; Lozy T; Ip A; Shier K; Prakash VP; Starolis M; Ansari S; Goldgirsh K; Kim S; Pelliccia MC; Mccutchen A; Megalla M; Gunning TS; Kaufman HW; Meyer WA; Perlin DS
Microbiol Spectr; 2024 Mar; 12(3):e0205023. PubMed ID: 38353557
[TBL] [Abstract][Full Text] [Related]
12. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
[TBL] [Abstract][Full Text] [Related]
13. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
[TBL] [Abstract][Full Text] [Related]
14. A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection.
Routhu NK; Gangadhara S; Lai L; Davis-Gardner ME; Floyd K; Shiferaw A; Bartsch YC; Fischinger S; Khoury G; Rahman SA; Stampfer SD; Schäfer A; Jean SM; Wallace C; Stammen RL; Wood J; Joyce C; Nagy T; Parsons MS; Gralinski L; Kozlowski PA; Alter G; Suthar MS; Amara RR
Sci Immunol; 2022 Jun; 7(72):eabo0226. PubMed ID: 35357886
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study.
Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
Clin Infect Dis; 2024 May; ():. PubMed ID: 38801746
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
García-Arriaza J; Garaigorta U; Pérez P; Lázaro-Frías A; Zamora C; Gastaminza P; Del Fresno C; Casasnovas JM; Sorzano CÓS; Sancho D; Esteban M
J Virol; 2021 Mar; 95(7):. PubMed ID: 33414159
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.
Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
EClinicalMedicine; 2023 May; 59():101983. PubMed ID: 37128256
[TBL] [Abstract][Full Text] [Related]
18. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
19. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
[TBL] [Abstract][Full Text] [Related]
20. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
